Clervonafusp alfa Antibody
Clervonafusp alfa (VAL-1221) is a dual-targeting fusion protein therapeutic candidate for Pompe disease research. It combines a cell-penetrating Fab for cytosolic glycogen clearance via ENT-2 with recombinant human GAA for lysosomal degradation via M6PRs. This mechanism has been investigated in both cellular models and in vivo studies for late-onset Pompe disease.
Product Specifications
Target
Glucosidase, glycosidase
Clonality
Recombinant
Conjugation
Unconjugated
Field of Research
Metabolism Research
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
